Mechanism of Action of Prostate Stem Cell Antigen Targeted Antibody Therapy and Its Relevance to Clinical Application in Prostate Cancer
Abstract
We have recently demonstrated that a monoclonal antibody against prostate stem cell antigen (PSCA) can exert anti-tumor activity in a xenograft animal model, suggesting oncogenic activity of PSCA in prostate cancer. Therefore the our goal is to elucidate the role of PSCA in the development of prostate cancer. A better understanding of PSCA function and its antibody activity will enable rational patient selection and trial design, all of which are particularly relevant to subsequent clinical trials of PSCA antibody. There were difficulties in using the LAPC9 xenograft cells to study the effect of suppressing PSCA, but we have since established conditions for infecting LAPC9 xenograft tumor cells in vitro, and confirmed knockdown ability of siPSCA lentivirus. We have examined PSCA-/-/Nkx3.1-/- double knockout mice at early time point and find no difference in the lagged time to PIN formation compared to control group. We have also recognized the difficulty in generating the PSCA-/- /conditional PTEN-/- compound mice, and have engaged in an alternative approach by using the tissue recombination assay.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2007
- Accession Number
- ADA468055
Entities
People
- Chau Tran
- Robert Reiter
Organizations
- University of California, Los Angeles